Zoledronic acid hydrate, Catalog: 2653


(1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl)diphosphonic acid; NDC-zoledronate; zoledronate; Zometa; Reclast ; CGP 42446; CGP42446A; ZOL 446


Alternate Names (1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl)diphosphonic acid; NDC-zoledronate; zoledronate; Zometa; Reclast ; CGP 42446; CGP42446A; ZOL 446

Appearance Crystaline solid

CAS # 165800-06-6

Molecular Formula C₅H₁₂N₂O₈P₂

Molecular Weight 290.1

Purity ≥ 98%

Solubility PBS (~1.6 mg/ml)


InChi InChI=1S/C5H10N2O7P2.H2O/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7;/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14);1H2


PubChem CID 121586

MDL Number MFCD08448695

Handling Protect from air and moisture

Storage Conditions -20°C

Shipping Conditions Gel Pack

Usage For Research Use Only! Not For Use in Humans.

Handling Do not take it internally. Wear a glove and mask when handling the product. Protect from air and moisture.


Zoledronic acid is a third-generation bisphosphonate that inhibits the prenylation of GTPases critical to the signaling events related to osteoclast-mediated bone resorption. It displays high affinity for hydroxyapatite (Ki = 3.47 μM) and binds directly to mineralized bone where it decreases bone resorption by inhibiting osteoclast proliferation and inducing osteoclast apoptosis. At micromolar concentrations, zoledronic acid demonstrates antitumor effects in vitro against breast, prostate, and myeloma cancer cells by inducing cytostasis and prevents bone metastases through its inhibitory effects on adhesion molecules, tumor cell invasion, and angiogenesis. Zoledronic acid has been used in the treatment of osteoporosis, Paget’s disease, metastatic bone disease, multiple myeloma, hypercalcemia of malignancy, and skeletal-related events associated with metastatic castrate-resistant prostate cancer.